NCT05281718View on ClinicalTrials.gov

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

March 7, 2024

Study Completion Date

July 14, 2024

Conditions

Hemophilia A

Interventions

DRUG

Factor IX

Factor IX is on of the substrates of emicizumab.

Trial Locations (2)

70001

Tulane University Lakeside Hospital and Clinics, Metairie

70112

University Medical Center New Orleans, New Orleans

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Tulane University

OTHER